The Board of Directors of DanCann Pharma A/S convenes an Extraordinary General Meeting and proposes that the Meeting resolves a directed share issue
The Board of Directors of DanCann Pharma A/S (publ) (“DanCann Pharma” or “the Company”) has today decided to convene an Extraordinary General Meeting of the Company on 23 July 2021 and proposes that the Board of Directors have the mandate to resolve a directed issue. Notice of the Extraordinary General Meeting is published and attached in this press release.The CEO of DanCann Pharma, Jeppe Krog Rasmussen, comments: I am pleased to announce that we in close contact with close parties and investors in DanCann Pharma today call for an Extraordinary General Meeting due to the proposal to